Comparative Pharmacology
Head-to-head clinical analysis: MPI STANNOUS DIPHOSPHONATE versus STRONTIUM CHLORIDE SR 89.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI STANNOUS DIPHOSPHONATE versus STRONTIUM CHLORIDE SR 89.
MPI STANNOUS DIPHOSPHONATE vs STRONTIUM CHLORIDE SR-89
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stannous diphosphonate is a radiopharmaceutical agent that forms a complex with technetium-99m; it localizes to areas of increased bone turnover by chemisorption to hydroxyapatite crystals, thereby enabling bone scintigraphy.
Strontium-89 is a calcium mimetic that localizes to bone, particularly areas of increased osteoblastic activity, emitting beta radiation that causes DNA damage and cell death in metastatic tumor cells.
Adult: 1-4 mg administered intravenously, single dose for bone scintigraphy.
148 MBq (4 mCi) intravenously over 1-2 minutes, single dose. Repeat after 3-6 months if needed.
None Documented
None Documented
Terminal elimination half-life: Approximately 2.5 hours for the diphosphonate component; the stannous ion is cleared more slowly. Clinically, this allows rapid bone uptake and background clearance for imaging within 2–4 hours post-injection.
Terminal elimination half-life: 50.5 days (range 33–65 days). Reflects slow clearance from bone; clinical effect persists due to long skeletal retention.
Renal: >90% of the administered dose is excreted unchanged in the urine within 24 hours. Biliary/fecal: Minimal (<2%).
Primarily renal (urinary) excretion; approximately 50-80% of absorbed dose eliminated via urine over 7 days. Fecal elimination is negligible (<5%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical